Journal: The Plant Journal

Article Title: The Arabidopsis cyclin-dependent kinase-activating kinase CDKF;1 is a major regulator of cell proliferation and cell expansion but is dispensable for CDKA activation

doi: 10.1111/j.1365-313x.2009.03884.x

Figure Lengend Snippet: Figure 5. The activities of cyclin-dependent kinase activating kinases CDKA and CDKB are not reduced in the cdkf;1-1 mutants. (a), (b) Protein levels and kinase activities of CDKA and CDKB in the wild-type and the cdkf;1-1 mutants. Protein extracts (10 lg for CDKA, 40 lg for CDKB and 5 lg for actin) from 10-day-old seedlings (a) or calli (b) were subjected to immunoblotting with specific antibodies. A kinase assay was conducted with immunoprecipitates by using histone H1 as a substrate. (c) Detection of the phosphorylated form of CDKA;1. Protein extracts (60 lg) from calli were incubated with or without lambda protein phosphatase (left), or depleted with anti-CDKA;1 antibody (right). Then the samples were subjected to immunoblotting with anti-CDKA;1 or anti-phospho-Cdc2 (Thr161) antibody. CDKA-P indicates CDKA;1 phosphorylated within the T-loop. (d) Protein extracts (60 lg) from calli of wild-type plants and the cdkf;1-1 mutants were subjected to immunoblotting with anti-phospho-Cdc2 (Thr161) antibody. Bands with an asterisk representing non-specific cross-reactions with the antibody.

Article Snippet: Commercial antibodies used include anti-actin antibody (MP Biomedicals, http:// www.mpbio.com/) and anti-phospho-Cdc2 (Thr161) antibody (Cell Signaling Technology, http://www.cellsignal.com/).

Techniques: Western Blot, Kinase Assay, Incubation

Journal: International Journal of Molecular Sciences

Article Title: Damage of Neuroblastoma Cell SH-SY5Y Mediated by MPP + Inhibits Proliferation of T-Cell Leukemia Jurkat by Co-Culture System

doi: 10.3390/ijms150610738

Figure Lengend Snippet: One hundred micro mole per liter MPP + -treated co-culture medium of SH-SY5Y and U87 cells induced Jurkat cell G2/M cell-cycle checkpoint. Jurkat cells treated with or without MPP + as background control, Jurkat cells incubated with the conditioned media of co-culture system treating without MPP + as control. ( a ) Cell cycle of G2/M phase of Jurkat cells was increased after 100 µM MPP + application compared to control medium without MPP + . ▲ means the position of Dip G1 and Dip G2; Dip G1 is the left red peak and Dip G2 is the right red peak; ( b ) Statistical analysis for the effect of conditioned media after 100 µM MPP + application on inducing cell cycle arrested. ** p < 0.01, compared with Jurkat cells in co-culture medium without MPP + applied; ( c ) Western blot assay for the G2/M cell-cycle checkpoint-related proteins. Phosphorylation of CDC2 was increased while Cyclin B1 decreased in protein level of Jurkat cells in MPP + -treated co-culture medium; ( d ) Quantification of intensities of CyclinB1/β-actin by Bio-Rad imaging-lad 4.0 software (Bio-Rad, Richmond, CA, USA). * p < 0.05 compared with Jurkat cells in co-culture medium without MPP + applied; ( e ) Quantification of intensities of p-CDC2/CDC2 by Bio-Rad imaging-lad 4.0 software. * p < 0.05 compared with Jurkat cells in co-culture medium without MPP + applied.

Article Snippet: Human neuroblastoma cell line SH-SY5Y were obtained from Xuanwu Hospital (Beijing, China) as a gift; human glioblastoma multiform cell line U87 and T-cell leukemia Jurkat cells were purchased from Peking Union Medical College (Beijing, China); caspase3/7 (Lot No: 0000054568) and caspase8 (Lot No: 0000052766) kit purchased from Promega (Madison, WI, USA); annexin V-PI flow cytometry analysis kit purchased from Keyueda (Beijing, China; Cat No: KTK101-100); cell-cycle flow cytometry analysis kit purchased from Keyueda (Cat No: KTK102-100); MPP + purchased from Sigma (St. Louis, MO, USA; Cat No: D048-1G); MTT purchased from Genview (Houston, TX, USA; Cat No: JT343), MTS purchased from Promega (Madison, WI, USA, Cat No: G111B), phenazinemethosulfate (PMS) purchased from Sigma (St. Louis, MO, USA; Cat No: P9625); DMSO purchased from Sigma (Cat No: D8428), imobilon ® -P Transfer Membrane (Lot No: K2KA7282EK) purchased from Millipore (Billerica, MA, USA); Antibodies for β-actin (Billerica MA, USA, Lot No: 3700S), CyclinB1 (Beverly, MA, USA, Lot No: P14635), CDC2 (Beverly, MA, USA, Lot No: 9112S), p-Cdc2 (Beverly, MA, USA, Lot No: 2543S) purchased from Cell Signaling Technology.

Techniques: Co-Culture Assay, Control, Incubation, Western Blot, Phospho-proteomics, Imaging, Software

Journal: Archives of oral biology

Article Title: A novel T-cell proliferation-associated gene predicts prognosis and reveals immune infiltration in patients with oral squamous cell carcinoma.

doi: 10.1016/j.archoralbio.2023.105719

Figure Lengend Snippet: Fig. 3. Development of a T-lymphocyte proliferation regulator-related prognostic signature. (a) Univariable Cox hazard analyses were completed on T-lymphocyte proliferation regulator pairs. (b) LASSO variable trajectory plots were screened for non-zero variables satisfying the lambda.min coefficient by ten-fold cross-vali dation. (c) Venn diagrams showed that T-lymphocyte proliferation regulators with statistical significance in univariable Cox hazard analyses and non-zero variables with lambda.min coefficients in LASSO variable trajectory plots and baseMean > 1000 that satisfied the above three conditions were screened out as the T- lymphocyte proliferation regulator signature (RAN, CDK1, CDK2) for prognostic risk model construction. (d) Curves of the LASSO coefficients for the three-T- lymphocyte proliferation regulator signature. (e, f) Differences in survival between high-risk and low-risk patients in the training and validation groups. (g, h) ROC curves at 1, 3 and 5 years for the training and validation groups. (i) Prognostic column line graph. LASSO, least absolute shrinkage and selection operator; ROC, receiver operating characteristic.

Article Snippet: AntiRAN primary antibody (dilution 1:250), anti-CDK1 primary antibody (dilution 1:250), and anti-CDK2 primary antibody (dilution 1:250) were purchased from Proteintech (Wuhan, China) and diluted in phosphatebuffered saline.

Techniques: Biomarker Discovery, Selection

Journal: Archives of oral biology

Article Title: A novel T-cell proliferation-associated gene predicts prognosis and reveals immune infiltration in patients with oral squamous cell carcinoma.

doi: 10.1016/j.archoralbio.2023.105719

Figure Lengend Snippet: Fig. 4. (a-c) Survival analysis based on the T-lymphocyte proliferation regulator signature (RAN, CDK1, CDK2). (d-f) ROC curves of the T-lymphocyte proliferation regulator signature (RAN, CDK1, CDK2) at 1, 3, and 5 years. (g) Risk factor visualisation. (h) Clinical correlation heat map analysis. ROC, receiver operating characteristic.

Article Snippet: AntiRAN primary antibody (dilution 1:250), anti-CDK1 primary antibody (dilution 1:250), and anti-CDK2 primary antibody (dilution 1:250) were purchased from Proteintech (Wuhan, China) and diluted in phosphatebuffered saline.

Techniques:

Journal: Archives of oral biology

Article Title: A novel T-cell proliferation-associated gene predicts prognosis and reveals immune infiltration in patients with oral squamous cell carcinoma.

doi: 10.1016/j.archoralbio.2023.105719

Figure Lengend Snippet: Fig. 5. Immune infiltration analysis (a-c) Infiltration analysis of the T-lymphocyte proliferation regulator signature (RAN, CDK1, CDK2) in 24 immune cell sub populations. (d) Enrichment fraction of each infiltrating cell type expressed between high-risk and low-risk patients. (e) Differences in the StromalScore, Immu neScore, and ESTIMATEScore between high-risk and low-risk patients. *p < 0.05; * *p < 0.01; * **p < 0.001; ns, not statistically significant. (f) Differences in the proportion of PD-1/PD-L1 in high-risk and low-risk patients.

Article Snippet: AntiRAN primary antibody (dilution 1:250), anti-CDK1 primary antibody (dilution 1:250), and anti-CDK2 primary antibody (dilution 1:250) were purchased from Proteintech (Wuhan, China) and diluted in phosphatebuffered saline.

Techniques:

Journal: Archives of oral biology

Article Title: A novel T-cell proliferation-associated gene predicts prognosis and reveals immune infiltration in patients with oral squamous cell carcinoma.

doi: 10.1016/j.archoralbio.2023.105719

Figure Lengend Snippet: Fig. 6. T-lymphocyte proliferation regulator signature expression in OSCC TME-associated cells. (a) Annotation of all cell types in GSE103322 and the percentage of each cell type. (b) Percentages and expression levels of RAN, CDK1, and CDK2. OSCC, oral squamous cell carcinoma; TME, tumour microenvironment.

Article Snippet: AntiRAN primary antibody (dilution 1:250), anti-CDK1 primary antibody (dilution 1:250), and anti-CDK2 primary antibody (dilution 1:250) were purchased from Proteintech (Wuhan, China) and diluted in phosphatebuffered saline.

Techniques: Expressing

Journal: Archives of oral biology

Article Title: A novel T-cell proliferation-associated gene predicts prognosis and reveals immune infiltration in patients with oral squamous cell carcinoma.

doi: 10.1016/j.archoralbio.2023.105719

Figure Lengend Snippet: Fig. 8. T-lymphocyte proliferation regulator signature (RAN, CDK1, and CDK2) combined with the Human Protein Atlas database and immunohistochemical assays to analyze the protein expression levels. Scale bar = 50 µm.

Article Snippet: AntiRAN primary antibody (dilution 1:250), anti-CDK1 primary antibody (dilution 1:250), and anti-CDK2 primary antibody (dilution 1:250) were purchased from Proteintech (Wuhan, China) and diluted in phosphatebuffered saline.

Techniques: Immunohistochemical staining, Expressing

Journal: Archives of oral biology

Article Title: A novel T-cell proliferation-associated gene predicts prognosis and reveals immune infiltration in patients with oral squamous cell carcinoma.

doi: 10.1016/j.archoralbio.2023.105719

Figure Lengend Snippet: Fig. 7. Drug-sensitivity analysis of the T-lymphocyte proliferation regulator signature (RAN, CDK1, and CDK2).

Article Snippet: AntiRAN primary antibody (dilution 1:250), anti-CDK1 primary antibody (dilution 1:250), and anti-CDK2 primary antibody (dilution 1:250) were purchased from Proteintech (Wuhan, China) and diluted in phosphatebuffered saline.

Techniques: